Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Chronic Hepatitis C Clinical Trial

Official title:
An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus Ribavirin in Vietnam

Status Withdrawn

Clinical Trial Summary

This study is designed to assess the safety and tolerability of boceprevir dosed 800 mg three times daily (TID) orally (PO) in combination with Peginterferon alfa-2b (PEG2b) 1.5 mcg/kg once a week (QW) administered subcutaneously (SC) plus ribavirin (RBV) (800 to 1400 mg/day) PO in Response Guided Therapy (RGT) in adult Vietnamese subjects with Chronic Hepatitis C, Genotype 1 (CHC GT1) who failed prior treatment with any interferon and ribavirin in Vietnam.

Clinical Trial Description

Each participant will participate in the trial for a maximum of 80 weeks from the time the participant signs the Informed Consent Form (ICF) through the final contact. After a Screening phase of approximately 4 to 8 weeks, each participant will receive treatment for approximately 36-48 weeks depending on response at Treatment Week 8.

A 4-week lead-in period with PEG2b plus RBV will be followed by 32 weeks boceprevir plus PEG2b/RBV. At treatment Week 36 participants will be assigned to the following treatments depending on the virologic response at Week 8 and cirrhotic status:

1. For non-cirrhotic participants with undetectable hepatitis C virus (HCV)-RNA on Week 8, all treatment will be discontinued at Week 36.

2. For non-cirrhotic participants with detectable HCV-RNA on Week 8, only boceprevir treatment will be discontinued at Week 36 and PEG2b and RBV treatment will continue to Week 48.

3. For cirrhotic participants, the boceprevir plus PEG2b/RBV treatment will continue to Week 48.

The study has a futility rule at Week 12 at which point all subjects with detectable HCV-RNA levels will be discontinued. All participants will have a post-treatment follow-up period of at least 24 weeks. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01641666
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Withdrawn
Phase	Phase 3
Start date	May 2014
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01937975` - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)	Phase 1
Completed	`NCT03673696` - The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects	Phase 1
Completed	`NCT02250001` - Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C	N/A
Completed	`NCT03088917` - 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Completed	`NCT02207088` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease	Phase 3
Not yet recruiting	`NCT02865369` - Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment	N/A
Recruiting	`NCT02638233` - Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy	Phase 4
Not yet recruiting	`NCT02511496` - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia	N/A
Not yet recruiting	`NCT01949168` - A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV	Phase 2
Completed	`NCT02788682` - Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy	N/A
Completed	`NCT01439776` - Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients	Phase 4
Recruiting	`NCT01360892` - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography	N/A
Recruiting	`NCT01360879` - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease	N/A
Completed	`NCT00968357` - Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed	Phase 2
Terminated	`NCT00962936` - Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection	Phase 1/Phase 2
Recruiting	`NCT00575627` - Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels	Phase 4
Recruiting	`NCT01178749` - Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments	N/A
Completed	`NCT00537407` - A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment	Phase 2
Recruiting	`NCT00370617` - Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	Phase 4
Completed	`NCT01684787` - Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients	Phase 4